Effect of double antigen bridging immunoassay format on antigen coating concentration dependence and implications for designing immunogenicity assays for monoclonal antibodies

被引:16
作者
Bourdage, JS [1 ]
Lee, TN [1 ]
Taylor, JM [1 ]
Willey, MB [1 ]
Brandt, JT [1 ]
Konrad, RJ [1 ]
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA
关键词
enzyme immunoassay; double antigen; bridging; antigen coating;
D O I
10.1016/j.jpba.2005.03.037
中图分类号
O65 [分析化学];
学科分类号
070302 [分析化学]; 081704 [应用化学];
摘要
The double antigen bridging immunoassay has been used extensively for detection of immunogenicity responses to therapeutic monoclonal antibodies. We have analyzed parameters affecting performance of this type of immunoassay including microtiter plate antigen coating concentration, enzyme-labeled antigen conjugate dilution and assay format (one-step versus two-step). We present results demonstrating that the format of the assay has a significant impact on the optimal parameters to maximize assay performance. A one-step assay format achieves maximal sensitivity across a broad range of coating concentrations and at a lower concentration of conjugate than that in a two-step format. In contrast, a two-step format requires very low coating concentrations and higher conjugate concentrations to achieve maximal sensitivity and suffers from significantly reduced sensitivity at higher coating concentrations. Together, these findings indicate that a one-step assay format can greatly reduce the effect of coating concentration variation on assay performance. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:685 / 690
页数:6
相关论文
共 17 条
[1]
Simultaneous quantitation of diphtheria and tetanus antibodies by double antigen, time-resolved fluorescence immunoassay [J].
Aggerbeck, H ;
NorgaardPedersen, B ;
Heron, I .
JOURNAL OF IMMUNOLOGICAL METHODS, 1996, 190 (02) :171-183
[2]
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].
Baert, F ;
Noman, M ;
Vermeire, S ;
Van Assche, G ;
D'Haens, G ;
Carbonez, A ;
Rutgeerts, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608
[3]
Börjesson PKE, 2003, CLIN CANCER RES, V9, p3961S
[4]
CHATENOUD L, 1993, CLIN TRANSPLANT, V7, P422
[5]
Final results of the ReoPro Readministration Registry [J].
Dery, JP ;
Braden, GA ;
Lincoff, AM ;
Kereiakes, DJ ;
Browne, K ;
Little, T ;
George, BS ;
Sane, DC ;
Cines, DB ;
Effron, MB ;
Mascelli, MA ;
Langrall, MA ;
Damaraju, L ;
Barnathan, ES ;
Tcheng, JE .
AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (08) :979-984
[6]
Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-D33 monoclonal antibody HuM195 [J].
Feldman, E ;
Kalaycio, M ;
Weiner, G ;
Frankel, S ;
Schulman, P ;
Schwartzberg, L ;
Jurcic, J ;
Velez-Garcia, E ;
Seiter, K ;
Scheinberg, D ;
Levitt, D ;
Wedel, N .
LEUKEMIA, 2003, 17 (02) :314-318
[7]
DEMONSTRATION OF HUMAN AUTOANTIBODIES BY QUANTITATIVE ENZYME IMMUNOASSAYS [J].
GRIPENBERG, M ;
KURKI, P .
JOURNAL OF IMMUNOLOGICAL METHODS, 1986, 92 (02) :145-159
[8]
Safety of tumour necrosis factor-α antagonists [J].
Khanna, D ;
McMahon, M ;
Furst, DE .
DRUG SAFETY, 2004, 27 (05) :307-324
[9]
Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection [J].
Lacaze-Masmonteil, T ;
Seidenberg, J ;
Mitchell, I ;
Cossey, V ;
Cihar, M ;
Csader, M ;
Baarsma, R ;
Valido, M ;
Pollack, PF ;
Groothuis, JR .
DRUG SAFETY, 2003, 26 (04) :283-291
[10]
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer [J].
Milowsky, MI ;
Nanus, DM ;
Kostakoglu, L ;
Vallabhajosula, S ;
Goldsmith, SJ ;
Bander, NH .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) :2522-2531